MCL-1 inhibition in cancer treatment

Myeloid cell leukemia-1 (MCL-1), a member of antiapoptotic BCL-2 family proteins, is a key regulator of mitochondrial homeostasis. Frequent overexpression of MCL-1 in human primary and drug-resistant cancer cells makes it an attractive cancer therapeutic target. Significant progress has been made in...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Weiguo, Yang, Chao-Yie, Bai, Longchuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205821/
https://www.ncbi.nlm.nih.gov/pubmed/30425521
http://dx.doi.org/10.2147/OTT.S146228
_version_ 1783366243511697408
author Xiang, Weiguo
Yang, Chao-Yie
Bai, Longchuan
author_facet Xiang, Weiguo
Yang, Chao-Yie
Bai, Longchuan
author_sort Xiang, Weiguo
collection PubMed
description Myeloid cell leukemia-1 (MCL-1), a member of antiapoptotic BCL-2 family proteins, is a key regulator of mitochondrial homeostasis. Frequent overexpression of MCL-1 in human primary and drug-resistant cancer cells makes it an attractive cancer therapeutic target. Significant progress has been made in the development of small-molecule MCL-1 inhibitors in recent years, and three MCL-1 selective inhibitors have advanced to clinical trials. This review briefly discusses recent advances in the development of small molecules targeting MCL-1 for cancer therapy.
format Online
Article
Text
id pubmed-6205821
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62058212018-11-13 MCL-1 inhibition in cancer treatment Xiang, Weiguo Yang, Chao-Yie Bai, Longchuan Onco Targets Ther Review Myeloid cell leukemia-1 (MCL-1), a member of antiapoptotic BCL-2 family proteins, is a key regulator of mitochondrial homeostasis. Frequent overexpression of MCL-1 in human primary and drug-resistant cancer cells makes it an attractive cancer therapeutic target. Significant progress has been made in the development of small-molecule MCL-1 inhibitors in recent years, and three MCL-1 selective inhibitors have advanced to clinical trials. This review briefly discusses recent advances in the development of small molecules targeting MCL-1 for cancer therapy. Dove Medical Press 2018-10-23 /pmc/articles/PMC6205821/ /pubmed/30425521 http://dx.doi.org/10.2147/OTT.S146228 Text en © 2018 Xiang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Xiang, Weiguo
Yang, Chao-Yie
Bai, Longchuan
MCL-1 inhibition in cancer treatment
title MCL-1 inhibition in cancer treatment
title_full MCL-1 inhibition in cancer treatment
title_fullStr MCL-1 inhibition in cancer treatment
title_full_unstemmed MCL-1 inhibition in cancer treatment
title_short MCL-1 inhibition in cancer treatment
title_sort mcl-1 inhibition in cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205821/
https://www.ncbi.nlm.nih.gov/pubmed/30425521
http://dx.doi.org/10.2147/OTT.S146228
work_keys_str_mv AT xiangweiguo mcl1inhibitionincancertreatment
AT yangchaoyie mcl1inhibitionincancertreatment
AT bailongchuan mcl1inhibitionincancertreatment

Ejemplares similares